Guardant Health (GH) officer discloses December 2025 stock sales

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported a series of open-market sales of the company’s common stock on December 5, 2025. The Form 4 shows multiple sale transactions at weighted average prices including $101.4027, $102.0946, $103.2528, $103.9717, $105.9863 and $106.7081 per share, with each line representing shares sold across narrower intraday price ranges from $100.710 up to $106.990 per share. Each transaction is coded as a sale and reported as directly held. Following these sales, Freeman’s directly owned position in Guardant Health common stock is disclosed as 25,987 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freeman Chris

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/05/2025		S		478	D	$101.4277(1)	56,961	D
Common Stock	12/05/2025		S		744	D	$102.306(2)	56,217	D
Common Stock	12/05/2025		S		372	D	$103.4815(3)	55,845	D
Common Stock	12/05/2025		S		244	D	$104.0985(4)	55,601	D
Common Stock	12/05/2025		S		228	D	$106.6322(5)	55,373	D
Common Stock	12/05/2025		S		4,084	D	$101.4027(6)	51,289	D
Common Stock	12/05/2025		S		11,969	D	$102.0946(7)	39,320	D
Common Stock	12/05/2025		S		3,414	D	$103.2528(8)	35,906	D
Common Stock	12/05/2025		S		6,555	D	$103.9717(9)	29,351	D
Common Stock	12/05/2025		S		400	D	$105.9863(10)	28,951	D
Common Stock	12/05/2025		S		2,964	D	$106.7081(11)	25,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.770 to $101.750. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.810 to $102.700. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.005 to $103.860. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.010 to $104.200. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

5. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.450 to $106.735. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

6. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.710 to $101.695. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

7. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.720 to $102.700. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

8. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.720 to $103.710. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

9. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.725 to $104.510. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

10. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.415 to $106.390. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

11. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.500 to $106.990. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Guardant Health (GH) report in this Form 4?

The filing reports that Chief Commercial Officer Chris Freeman sold multiple blocks of Guardant Health common stock in open-market transactions on December 5, 2025, all coded as sales.

What prices were Guardant Health (GH) shares sold for by the officer?

The sales were reported at weighted average prices such as $101.4027, $102.0946, $103.2528, $103.9717, $105.9863 and $106.7081 per share, with underlying trades occurring in price ranges from $100.710 to $106.990 per share.

How many Guardant Health (GH) shares does Chris Freeman hold after these transactions?

After the reported sales, Chris Freeman is shown as directly owning 25,987 shares of Guardant Health common stock.

What is Chris Freeman’s role at Guardant Health (GH)?

Chris Freeman is identified as an Officer of Guardant Health, serving as the company’s Chief Commercial Officer.

Were any derivative securities reported in this Guardant Health (GH) Form 4?

The section for derivative securities is included in the form’s layout, but no specific derivative transactions or holdings are listed in the provided table.

How were the price ranges for the Guardant Health (GH) stock sales described?

Each sale line is described as a weighted average sales price covering multiple transactions, with the filing stating that shares were sold within specified price ranges such as $100.770 to $101.750 and up to $106.500 to $106.990 per share. The reporting person undertakes to provide detailed trade breakdowns upon request.